The agreement secures a critical raw material supply for Inmune Bio's CORDStrom platform, but as a clinical-stage company with no commercial sales, there is no near-term revenue catalyst. Traders should monitor clinical trial progress and regulatory milestones for CORDStrom in RDEB and oncology.
Price Chart
Executive Summary
Inmune Bio entered into an amended and restated Material Transfer and License Agreement with Anthony Nolan, securing long-term supply of umbilical cord tissue for its CORDStrom platform. The agreement, effective April 29, 2026, adds Inmune Bio as a party with joint liability for a 2% royalty on net sales (capped at £5 million annually) and extends the license to cover multiple indications including RDEB, oncology, and inflammatory diseases.
Key Financial Metrics
Key Facts
- Inmune Bio becomes a party to the agreement and jointly liable with its UK subsidiary for royalty payments.
- Anthony Nolan receives a 2% royalty on net sales of each Product, up to an annual cap of £5,000,000.
- The license covers initial indications: epidermolysis bullosa, osteoarthritis, intra-partum hypoxia, and solid tumors.
- Term extends to 10 years after first commercial sale of any Product.
- The agreement includes provisions for traceability, quality management, and GMP compliance.
Financial Impact
No immediate financial impact; potential future royalty obligation capped at £5M per year if products are commercialized.
Risk Factors
- No products have received regulatory approval; commercialization timeline uncertain.
- Royalty obligations may impact future margins if products reach market.
- Dependence on Anthony Nolan for consistent supply of umbilical cord tissue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-052231 |
| Document: ea0288685-8k_inmune.htm | 0001213900-26-052231 |
| Document: ea028868501ex99-1.htm | 0001213900-26-052231 |
| Document: 0001213900-26-052231-index-headers.html | 0001213900-26-052231 |
| Document: 0001213900-26-052231-index.html | 0001213900-26-052231 |
| Document: 0001213900-26-052231.txt | 0001213900-26-052231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $1.61 | awaiting T+60 | — | $1.52 (−5.59%) |
Sep 16, 2026 5w ago | 3 | $2.18 | awaiting T+60 | — | $1.52 (−30.28%) |
Jul 9, 2026 15w ago | Press Release | $1.79 $1.93 | ▲ +7.82% | ▲ +6.19% | $1.52 (−15.08%) |
Jul 1, 2026 16w ago | 8-K | $1.68 | awaiting T+60 | — | $1.52 (+9.52%) |
Jun 23, 2026 18w ago | 8-K | $1.35 | awaiting T+60 | — | $1.52 (+12.59%) |
Jun 17, 2026 18w ago | 8-K | $1.45 | awaiting T+60 | — | $1.52 (+4.83%) |
Jun 2, 2026 21w ago | 8-K | $1.32 $2.40 | ▲ +81.82% | ▲ +79.32% | $1.52 (+15.15%) |
May 7, 2026 24w ago | Press Release | $1.43 $1.91 | ▲ +33.57% | ▲ +28.73% | $1.52 (+6.29%) |
May 5, 2026 25w ago | 8-K | $1.52 $1.75 | ▲ +15.13% | ▲ +13.07% | $1.52 (−0.00%) |
Apr 30, 2026 25w ago | Press Release | $1.43 | awaiting T+60 | — | $1.52 (+6.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers